Cost-effectiveness of a pharmacist-led medication therapy management clinic for management of type 2 diabetes
Journal of the American Pharmacists Association · 2025
DOI: 10.1016/j.japh.2024.102253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Pharmacists Association, 2025. Verfasst von Mrinmayee Joshi und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Pharmacists, Medication Therapy Management. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Diabetes imposes a substantial public health burden. Involvement of clinical pharmacists in diabetes disease management can improve health outcomes while managing expenditure. OBJECTIVE: This study aimed to evaluate the lifetime cost-effectiveness of a pharmacist-led medication therapy management clinic (MTMC) compared to usual care for individuals with type 2 diabetes mellitus, from a U.S. payer perspective. METHODS: A cohort simulation Markov model was developed to simulate the occurrence of major complications of diabetes. Transition probabilities, MTMC treatment effects, health state costs, and utilities were based on data from electronic health records and published literature. Outcomes evaluated were lifetime costs, quality-adjusted life years (QALYs), and incremental cost-effective ratio (ICER). Sensitivity analyses were conducted on all model inputs; scenario analyses assessed the impact of preventing additional diabetes complications on economic outcomes, and of reduced MTMC visit frequency. RESULTS: Over a lifetime, MTMC resulted in $160,145 total costs and 6.73 QALYs; usual care resulted in $152,806 total costs and 6.65 QALYs. The ICER for MTMC compared to usual care was $93,375 per QALY gained, indicating cost-effectiveness at a willingness-to-pay threshold of $100,000 per QALY gained. Scenario analyses showed that modeling additional complications or reduced visit frequency lowered the ICER. The results were most sensitive to MTMC costs, and hazard ratios for occurrence of stroke, myocardial infarction, and renal failure. CONCLUSION: The study demonstrates the potential cost-effectiveness of integrating clinical pharmacy services into comprehensive care strategies. Findings support the broader coverage and reimbursement of such services to optimize clinical outcomes and reduce long-term health care costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
Joshi, M., Pham, C., Deng, H., Mathew, S., Norton, R. M., Kim, K., Touchette, D. R., & Tilton, J. J. (2025). Cost-effectiveness of a pharmacist-led medication therapy management clinic for management of type 2 diabetes. Journal of the American Pharmacists Association. https://doi.org/10.1016/j.japh.2024.102253
Vancouver
Joshi M, Pham C, Deng H, Mathew S, Norton RM, Kim K, et al. Cost-effectiveness of a pharmacist-led medication therapy management clinic for management of type 2 diabetes. Journal of the American Pharmacists Association. 2025. doi:10.1016/j.japh.2024.102253
BibTeX
@article{Joshi2025,
author = {Joshi, Mrinmayee and Pham, Christine and Deng, Huiwen and Mathew, Sheryl and Norton, Rachel M and Kim, Kibum and Touchette, Daniel R and Tilton, Jessica J},
title = {Cost-effectiveness of a pharmacist-led medication therapy management clinic for management of type 2 diabetes},
journal = {Journal of the American Pharmacists Association},
year = {2025},
doi = {10.1016/j.japh.2024.102253}
}
EUVIMED